For healthcare professionals

Estab­lished in the UK in 2008, Théa Phar­ma­ceu­ti­cals is built around 3 cen­tral pil­lars which form the foun­da­tion of our spir­it and suc­cess: inno­va­tion, edu­ca­tion and pro­fes­sion­al­ism. Our growth and suc­cess fol­lows a series of excit­ing prod­uct launch­es and acqui­si­tions mean­ing we now offer over 30 prod­ucts across a wide range of key ther­a­py areas serv­ing the com­plex needs of eye health professionals.

Over 10 years of outstanding ophthalmology in the UK

Ini­tial­ly in the UK Théa focused on the areas of Dry Eye, lid hygiene and eye nutri­tion but now offers an exten­sive prod­uct range to include aller­gy, anti-inflam­ma­to­ry, glau­co­ma, infec­tion, surgery and optometry. 

The com­pa­ny was amongst the first to intro­duce preser­v­a­tive-free eye drops, due to the well-known issues caused by such ingre­di­ents in oph­thal­mol­o­gy prod­ucts, most com­mon­ly Ben­za­lko­ni­um Chlo­ride (BAK). Théa works close­ly with the oph­thal­mol­o­gy depart­ments in numer­ous UK hos­pi­tals to devel­op high qual­i­ty solutions. 

Focused on innovation and education

Over the last decade, the com­pa­ny has grown from just five staff to a team of over 50 work­ing across three Busi­ness Units: Con­sumer, Med­ical and Sur­gi­cal. Théa is locat­ed in the IC5 build­ing at Keele Uni­ver­si­ty Sci­ence and Inno­va­tion Park and plans to expand even fur­ther over the com­ing years with the goal of becom­ing the lead­ing oph­thalmic sup­pli­er in the UK

Guid­ed by three strate­gic pil­lars: Dri­ving Inno­va­tion, Edu­ca­tion and Pro­fes­sion­al­ism in improv­ing Eye Health”, Théa con­tin­ues to invest heav­i­ly in education. 

This is demon­strat­ed by our award-win­ning Dry Eye Project’ (replaced by the Théa Eye Health Con­fer­ence); the pres­ti­gious Moor­fields Inter­na­tion­al Glau­co­ma Sym­po­sium; and Théa Birm­ing­ham Corneal Meet­ing, launched in 2015. Théa Phar­ma­ceu­ti­cals is com­mit­ted to sup­port­ing oph­thalmic pro­fes­sion­als and to hav­ing a pos­i­tive impact on the eye health of all those who use our prod­ucts as inspired by our glob­al par­ent com­pa­ny.

To see more about our glob­al ini­tia­tives please click below.

Théa Global

The Théa Approach

Théa have been pio­neers in oph­thal­mol­o­gy for 150 years, spe­cial­is­ing in preser­v­a­tive-free for­mu­la­tions and inno­v­a­tive deliv­ery sys­tems. We are com­mit­ted to mak­ing preser­v­a­tive-free prod­ucts acces­si­ble and cost-effec­tive for patients and the NHS and aim to invest in edu­ca­tion­al pro­grammes to ben­e­fit both health­care pro­fes­sion­als and patients.

Abak Bottle

Théa invent­ed the first mul­ti-dose bot­tle capa­ble of dis­pens­ing preser­v­a­tive-free eye drops: the ABAK® bot­tle. The ABAK® bot­tle is a high-secu­ri­ty, high-tech­nol­o­gy dis­penser which deliv­ers up to 300 drops through a fil­ter which pre­vents micro­bial con­t­a­m­i­na­tion. Con­tin­u­al inno­va­tions have made it small­er, more user-friend­ly and more effec­tive. The con­tents can now be used for up to 3 months after open­ing as opposed to between 2 and 4 weeks for a clas­si­cal pre­served mul­ti-dose bot­tle. Pro­tect­ed by patents, the design has been specif­i­cal­ly cre­at­ed so that patients with weak­er hand strength can instill drops; — it requires only 13 of the strength need­ed by oth­er bot­tles.1

  1. Con­nor, AJ & Sev­ern, PS. Eye (2011) 25 466 – 469

The History of Théa UK

2008 - Théa Pharmaceuticals established

Théa launched Blephasol, Blephaclean and Blephagel products into the UK. This marked Thea’s partnership with optometrists, meeting the unmet need for those with conditions such as MGD and blepharitis in the UK.

2008 - Hyabak

Hyabak, preservative-free sodium hyaluronate dry eye drops in Théa’s innovative preservative free bottle system, the ABAK Bottle. Tha launch of Hyabak made preservative free a cost-effective option of treating dry eye.

2008 - Nutrof Total

Innovation in nutrition. Théa launched Nutrof Total which, over the years, has been further improved with the addition of resveratrol alongside well established molecules including lutein, zeaxanthin and omega 3.

2009 - Virgan

A powerful antiviral, Ganciclovir in a gel format for the treatment of acute herpetic keratitis.

2010 - Blephasteam

Innovation driven by research. Blephasteam was designed to provide moist, warm heat shown to be most effective in relieving the symptoms of Meibomian Gland Dysfunction and associated diseases.

2011 - Azyter

The first 3-day topical antibiotic treatment which is preservative-free and licensed for both adults and children over 3 months.

2011 - Mydriasert

The acquisition of the ophthalmic insert Mydriasert, marked Théa’s entrance into the cataract surgery arena, working with cataract services to support more efficient services.

2011 - Thealoz

In a new advance in the approach to dry eye treatment, Théa launched Thealoz, a unique drop containing trehalose, a molecule with bioprotective properties to protect the corneal and conjunctival epithelia from desiccation.

2011 - Tiopex

A novel presentation of preservative free timolol. Contained within a carbomber gel enhances residence time allowing it to be the only once daily preservative free timolol.

2012 - Otrivine Anthistin and Zaditen

The acquisition of Otrivine Anthisitin and Zaditen marked Théa's entrance into hay fever and allergy management.

2012 - Voltarol Ophtha Multidose and Unit Dose

The acquisition of Voltarol Ophtha widened Théa's anti-inflammatory offering into non-steroidals.

2013 - Blephagel PF

The revolutionary creation by Thea of the SteriFree tube enabled gels to be preservative-free. This year Blephagel became preservative-free.

2013 - Aprokam

After the publication of the pivotal 2007 ESCRS Study and the requirement for a licensed intracameral cefuroxime, Théa developed Aprokam to fill this unmet need.

2013 - Monopost

Using an innovative vehicle, protriaxin, Théa launched the first preservative-free latanoprost at a cost-effective price.

2014 - Hyabak Caps

An extension to Théa nutritional range, developed to support Dry Eye sufferers. It contains a high dose of Omega 3 and 6 fatty acids which have been shown to influence the severity of dry eye symptoms.

2014 - Thealoz Duo

The next generation of dry eye drop is realised by the launch of Thealoz duo. Containing not only sodium hyaluronate but also Trehalose to both protect the ocular surface and provide long lasting hydration. Backed by scientific evidence of its efficacy.

2014 - Dexafree

In response to the raising drug costs of preservative free dexamethasone drops, Théa launched Dexafree. A low cost, preservative-free dexamethasone drop.

2014 - Théa moved offices to Keele

2015 - Thealoz Duo Gel

Extending the Thealoz Duo range with Thealoz Duo Gel for patients with more severe Dry Eye symptoms who like a gel format and for night-time use.

2016 - Mydrane

The second country in the world to launch the first licensed intracameral mydriatic and anaesthetic combination for cataract surgery, further supporting hospitals to improve the efficiency of their cataract lists.

2017 - Blephaclean CE

Blephaclean was launched into hospitals after achieving a CE mark using the wealth of clinical evidence supporting its use in patients with blepharitis and around lowering the bacterial load on eyelids.

2018 - Softacort

The launch of Théa’s first soft steroid for the treatment of mild non-infectious allergic or inflammatory conjunctival diseases.

2018 - Moved to new offices in IC5

Théa’s success since 2008 allowed the move to larger, purpose-built offices in the new IC5 innovation centre on Keele University’s Science and Innovation Park.

2019 - Blephademodex

Théa launch Blephademodex in response to the growing need for a clinically proven wipe to combat demodex mite infestation.

2019 - Fixapost

Introducing Fixapost, the first preservative-free latanoprost-timolol fixed combination eye drops available in the UK.